In regards to the current strategy, company CEO, Kenneth Manzo stated, "We definitely plan to do more in-depth studies with much larger groups of subjects down the road, but with results like the ones have seen, we simply do not want to wait to get the product to the people that need it. As a licensed Pharmacist, I have been dealing with people who suffer from lactose intolerance for many years and it can be absolutely debilitating. Lacto-Freedom™ has the potential to offer life-changing relief to these people and that is something I do not want to hold back any longer."
The two major steps in getting Lacto-Freedom™ to consumers involves producing the product itself, and then encapsulating and packaging it. Manzo Pharmaceuticals has isolated and solidified relationships with firms to handle both of these tasks. The first major step in manufacturing Lacto-Freedom™, a process called riboprinting will take place as soon as the sample is sent to the new manufacturer. This will happen within the next few weeks or so, and then a process of testing, fermentation, purification, and microbiological studies in order to make sure the product is the highest quality possible while staying well within FDA guidelines. The entire process will take approximately five months provided everything goes as planned. This is very good news for those who are lactose intolerant, estimated to be approximately 25% of the US population and 75% of the world population, because it is very possible that Lacto-Freedom™ could be in consumers' hands this summer.
About Manzo Pharmaceuticals, Inc.
Manzo Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, and testing of patented and non-patented solutions and remedies. Most notable is a patented probiotic for lactose intolerance, and a natural remedy sleep aid. For more information follow the company on twitter at @manzopharma, and visit www.manzopharma.com.
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/manzo-pharmaceuticals-solidifies-deal-with-usa-based-manufacturers-to-begin-producing-the-companys-lactose-intolerance-probiotic-lacto-freedom-300240653.html
SOURCE Manzo Pharmaceuticals, Inc.